Compare JAGX & NDRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JAGX | NDRA |
|---|---|---|
| Founded | 2013 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.9M | 5.5M |
| IPO Year | 2014 | 2016 |
| Metric | JAGX | NDRA |
|---|---|---|
| Price | $0.87 | $4.47 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $60.00 | $30.00 |
| AVG Volume (30 Days) | ★ 104.5K | 14.4K |
| Earning Date | 04-07-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 82.42 | ★ 84.32 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $11,511,000.00 | N/A |
| Revenue This Year | $61.58 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.22 | $2.96 |
| 52 Week High | $8.00 | $9.83 |
| Indicator | JAGX | NDRA |
|---|---|---|
| Relative Strength Index (RSI) | 24.13 | 45.08 |
| Support Level | $0.60 | $4.15 |
| Resistance Level | $0.99 | $4.90 |
| Average True Range (ATR) | 0.09 | 0.31 |
| MACD | 0.03 | -0.00 |
| Stochastic Oscillator | 9.01 | 62.22 |
Jaguar Health Inc is a commercial-stage pharmaceutical company developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for gastrointestinal disease states in humans and animals. The Company focuses on conditions associated with overactive bowel, including chronic debilitating diarrhea, urgency, and bowel incontinence. It operates through two segments: animal health, which develops and commercializes products for animals, and human health, with the human health segment generating the maximum revenue and focusing on products such as Mytesi, focusing on human products, specifically Mytesi, approved for symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.
ENDRA Life Sciences Inc is engaged in the development of Thermo Acoustic Enhanced UltraSound (TAEUS) to visualize tissue like MRI at the cost and at the point of patient care. TAEUS is designed to work in concert with around 400,000 cart-based ultrasound systems in use globally today. TAEUS is initially focused on the measurement of fat in the liver as a means to assess and monitor Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH), chronic liver conditions that affect over one billion people globally, and for which there are no practical diagnostic tools. Beyond the liver, the firm is exploring several other clinical applications of TAEUS, including visualization of tissue temperature during energy-based surgical procedures.